Peter Beitsch
About Peter Beitsch
Peter Beitsch, MD (age 64) joined the Board in June 2024 and is an independent director. He is a surgical oncologist in private practice since 1994 with a focus on melanoma and breast cancer, trained at UT Southwestern, Parkland Hospital (general surgery residency 1986–1993), a two‑year NCI fellowship at MD Anderson (1988–1990), and a surgical oncology fellowship at John Wayne Cancer Institute; the Board states his clinical and research background supports guidance on the company’s RPPA technology platform . The Board determined Dr. Beitsch is independent under Nasdaq rules and that the Board’s composition is majority independent with independent directors meeting in executive session at least twice annually .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| American Society of Breast Surgeons | President; Program Director (Annual Meeting); Board Member; First Chair, Membership Committee | President 2013–2014; Program Director 2005; Board 2006–2009, 2012–2015; Membership Chair 2001–2004 | Leadership across governance, membership growth, program direction |
| Society of Surgical Oncology | Executive Committee | 2008–2010 | Executive oversight and strategy |
| American Board of Surgery | General Surgical Oncology Committee | 2013–2019 | Standards and certification input |
| American College of Surgeons | National Ultrasound Faculty | Not stated | Clinical training and practice standards |
| Targeted Medical Education (acquired by Aptitude Health in 2022) | Co‑founder; ongoing involvement | Co‑founder; acquisition in 2022 | Clinical trial and education platform development |
| Dallas Surgical Group | Surgeon | Ongoing | Clinical practice |
External Roles
| Organization | Role | Notes |
|---|---|---|
| Invitae | Involvement (unspecified capacity) | Biotech/genetic testing engagement noted by company |
| Aptitude Health (via Targeted Medical Education) | Relationship through TME acquisition | Targeted Medical Education acquired in 2022; Beitsch remains involved |
Board Governance
- Board size is five directors; Beitsch joined June 2024 alongside Matthew Schwartz .
- Independence: Board determined Beitsch and the other directors are independent under Nasdaq rules; independent directors hold executive sessions at least twice annually .
- Committee composition (2023): Audit Committee—Michael D. Pruitt (Chair), Maurice E. Evans, Cary W. Sucoff; Compensation Committee—Maurice E. Evans (Chair), Michael D. Pruitt, Cary W. Sucoff; Pruitt is designated as the audit committee financial expert . The director slate table denotes committee membership footnotes for Evans, Pruitt, and Sucoff; Beitsch is not listed with committee footnotes in the 2024 proxy .
- Attendance (context): Board held nine meetings in 2023; all directors at that time attended all meetings. Beitsch did not serve in 2023, so his attendance is not disclosed for that period .
Fixed Compensation
- Structure: Non‑employee directors receive annual equity grants (options/RSUs) and cash fees per Board and committee meeting; in 2023, non‑employee directors (Evans, Pruitt, Sucoff) were paid $11,250 per quarter and awarded 3,333 RSUs with immediate vesting; Beitsch did not serve in 2023 .
| Director (FY2023) | Fees Paid in Cash ($) | Stock Awards ($) | Total ($) |
|---|---|---|---|
| Maurice E. Evans | 45,000 | 14,300 | 59,300 |
| Michael D. Pruitt | 45,000 | 14,300 | 59,300 |
| Cary W. Sucoff | 45,000 | 14,300 | 59,300 |
| Peter Beitsch | — (not a director in 2023) | — | — |
Notes:
- RSU valuation is full fair value at grant date under ASC 718 .
- Equity plan overview and authority under the 2018 Plan described; options must be granted at or above FMV and are non‑transferable; plan administered by the Compensation Committee .
Performance Compensation
- No director‑specific performance metrics (e.g., TSR, EBITDA) or PSU structures are disclosed for Beitsch; the 2018 Plan permits performance awards broadly, but specific director performance metrics are not provided .
Other Directorships & Interlocks
- Public company directorships for Beitsch are not disclosed; narrative focuses on clinical and society leadership roles .
- The company acquired certain Theralink assets in May 2024; Beitsch is not disclosed as a Theralink director (Matthew Schwartz served on Theralink’s board) .
- No related‑party transactions associated with Beitsch are disclosed in the cited filings .
Expertise & Qualifications
- Medical education/training: UT Southwestern Medical School; Parkland general surgery residency (1986–1993); NCI fellowship at MD Anderson (1988–1990); surgical oncology fellowship at John Wayne Cancer Institute .
- Clinical specialty: Breast cancer and melanoma research/treatment; longstanding private practice since 1994 .
- Professional leadership: Executive roles across major surgical societies; program leadership; board service within professional organizations .
- Board relevance: Company states his oncology domain expertise supports RPPA platform oversight .
Equity Ownership
| Holder | Shares Beneficially Owned | % of Shares Outstanding |
|---|---|---|
| Peter Beitsch | 3,333 | <1% |
Context:
- Shares outstanding as of the Special Meeting Record Date (Jan 27, 2025): 2,071,812 .
Governance Assessment
- Independence and expertise: Strong independence designation and deep oncology expertise align with the company’s RPPA strategy, supporting Board effectiveness on technical oversight .
- Committee participation: As of the 2024 proxy, standing committees were staffed by Evans, Pruitt, and Sucoff; Beitsch was not listed on Audit/Compensation/Nominating membership, potentially limiting his direct influence on compensation and financial oversight processes at that time .
- Ownership alignment: Beneficial ownership of 3,333 shares (<1%) indicates limited “skin‑in‑the‑game”; director stock ownership guidelines and compliance status are not disclosed, constraining assessment of alignment incentives .
- Policies and controls: Company restricts speculative transactions/hedging and has adopted a Dodd‑Frank compliant clawback policy (2023), which are positive governance signals though primarily focused on executives .
- RED FLAGS: No specific conflicts or related‑party exposures tied to Beitsch are disclosed; low personal ownership is a modest alignment concern; absence of disclosed committee roles may reduce direct influence on key governance levers unless updated in later filings .